医学
长春瑞滨
内科学
转移性乳腺癌
肿瘤科
化疗
艾瑞布林
吉西他滨
乳腺癌
癌症
顺铂
作者
Aditya Bardia,Komal Jhaveri,Seock‐Ah Im,Sònia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez-Jáñez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen‐Shen Lu,Erika Hamilton,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky,Pedro Emanuel Rubini Liedke,Lu Xu,Rick M. Fairhurst,Sabrina S. Khan,Neelima Denduluri
摘要
Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI